- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Agenus Inc (AGEN)
Track today's live Agenus (AGEN) share price, performance and key data on this page with our current NASDAQ:AGEN stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Agenus share price on the NASDAQ exchange. Use the dropdown to switch exchange for the AGEN share price, head to our technical summary section, which provides analysis on Agenus share price buy/sell indicators using real-time data (or discuss the Agenus (AGEN) stock price today with other investors in the Agenus NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:AGEN share price (ISIN: US00847G8042) to enhance your trading decisions with our free investment tools and resources.
What Is the Agenus Inc Share Price Today?
The Agenus share price today is 6.630.
What Is the Stock Symbol for Agenus Inc
The stock symbol (or 'ticker') for Agenus Inc is "AGEN."
What Stock Exchange Does Agenus Inc Trade On?
Agenus Inc is listed and trades on the NASDAQ stock exchange.
Is Agenus Inc a Good Stock to Buy?
Determining whether Agenus (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:AGEN share price (ISIN: US00847G8042) to enhance your trading decisions with our free investment tools and resources.
What Is the Agenus Inc Share Price Today?
The Agenus share price today is 6.630.
What Is the Stock Symbol for Agenus Inc
The stock symbol (or 'ticker') for Agenus Inc is "AGEN."
What Stock Exchange Does Agenus Inc Trade On?
Agenus Inc is listed and trades on the NASDAQ stock exchange.
Is Agenus Inc a Good Stock to Buy?
Determining whether Agenus (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.484
6.950
52 wk Range
2.710
8.700
Earnings results expected in 13 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.4846.950
52 wk Range
2.7108.700
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AGEN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
30.000
Upside
+352.49%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 30.000
(+352.49% Upside)
Agenus Inc Earnings Call Summary for Q2/2025
- Agenus pursuing accelerated approval for BotVal immunotherapy; stock up 154% in 6 months, trading at $4.66
- Collaborating with Zydis Corporation to enhance manufacturing; initiating Phase III BATMAN trial with Canadian Cancer Trials Group
- Focus on colorectal cancer treatment, developing second-generation CTLA-4 immunotherapy and iNKT cell technology
- Preparing for ESMO presentation; CEO emphasizes ambitious goals beyond incremental improvements
- Revenue and EPS not disclosed; ongoing discussions for potential financing transactions noted
Last Updated: 12/09/2025, 16:40
Read Full TranscriptEarnings
Latest Release
11/05/2026
EPS / Forecast
1.02 / -0.65
Revenue / Forecast
33.7M / --
Compare AGEN to Peers and Sector
Metrics to compare | AGEN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAGENPeersSector | |
|---|---|---|---|---|
P/E Ratio | 4.6x | −1.3x | −0.3x | |
PEG Ratio | 0.04 | −0.14 | 0.00 | |
Price/Book | −1.3x | 2.2x | 2.6x | |
Price / LTM Sales | 2.4x | 8.8x | 3.0x | |
Upside (Analyst Target) | 354.5% | 144.7% | 56.3% | |
Fair Value Upside | Unlock | 18.4% | 9.8% | Unlock |
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Agenus (NASDAQ: AGEN) Share Price Today?
The Agenus stock price today is 6.630 USD.
What Stock Exchange Does Agenus (AGEN) Trade On?
Agenus is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Agenus?
The stock symbol (also called a 'ticker') for Agenus is "AGEN."
What Is the Current Agenus Market Capitalisation?
As of today, Agenus (NASDAQ: AGEN) market cap is 301.410M USD.
What Is Agenus's (AGEN) Earnings Per Share (TTM)?
The Agenus EPS is currently 1.933 (Trailing Twelve Months).
When Is the Next Agenus Earnings Date?
Agenus's next earnings report will be released on 11/08/2026.
Is AGEN a Buy or Sell From a Technical Analyst Perspective?
Based on today's Agenus moving averages and other technical indicators, the daily buy/sell signal for AGEN stock is Strong Buy.
How Many Times Has Agenus Stock Split?
Agenus has split 2 times. (See the AGEN stock split history page for full effective split date and price information.)
How Many Employees Does Agenus Have?
Agenus has 81 employees, based on their latest Companies House report.
What is the current trading status of Agenus (NASDAQ: AGEN)?
As of 29/07/2026, Agenus (AGEN) is trading at a share price of 6.630 USD, with a previous close of 6.600 USD. The stock has fluctuated within a day range of 6.484 USD to 6.950 USD, while its 52-week range spans from 2.710 USD to 8.700 USD.
What Is Agenus (AGEN) Price Target According to Analysts?
The average 12-month price target for Agenus is 30.000 USD, with a high estimate of 30 USD and a low estimate of 30 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +352.49% Upside potential.
What Is the AGEN Premarket Price?
AGEN's last pre-market stock price is 6.580 USD. The pre-market share volume is 6,840.000, and the stock has decreased by -0.020, or -0.300%.
What Is the AGEN After Hours Price?
AGEN's last after hours stock price is 6.680 USD, the stock has decreased by 0.050, or 0.750%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.